Albert A. Luderer was named Chief Executive Officer of Bionano Genomics, Inc. As of November 6, 2026, Bionano Genomics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 6, 2026 to June 5, 2026, naming 1 appointment and 1 departure (Form 8-K, May 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Bionano Genomics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Bionano Genomics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-06 to 2026-06-05. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Bionano Genomics, Inc. files it.
Also on the record for Bionano Genomics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 19, 2026 | Stake report, Schedule 13G, by Orin Hirschman | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Lind Global Fund III LP | 9.35% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Iroquois Capital Management, LLC | 4.99% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Lind Global Fund III LP | 9.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Richard Abbe | 4.99% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G, by Ayrton Capital LLC | 9.99% of the class | 5%+ stakes | Source |
| September 24, 2025 | Stake report, Schedule 13G, by Lind Global Fund III LP | 9.9% of the class | 5%+ stakes | Source |
| September 22, 2025 | Stake report, Schedule 13G, by CVI Investments, Inc. | 9.9% of the class | 5%+ stakes | Source |
| September 19, 2025 | Stake report, Schedule 13G, by Mitchell P. Kopin | 4.99% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13G, by Richard Abbe | 5.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Bionano Genomics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Bionano Genomics, Inc. and the records around it.
Bionano Genomics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Iroquois Capital Management, LLC also filed stake reports on 13 other companies: 22nd Century Group (Aug 2026), XWELL, Inc. (Aug 2026), Clearmind Medicine Inc. (Aug 2026)
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
Watch Bionano Genomics, Inc.
Get an email when Bionano Genomics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bionano Genomics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bionano Genomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bionano Genomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-05 | Reported | not named in the filing | 8-K, 2026-06-05 | ||
| 2026-05-06 | Out | 8-K, 2026-05-06 | |||
| 2026-05-06 | In | Chief Executive Officer | 8-K, 2026-05-06 |
Who leads Bionano Genomics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Albert A. Luderer, appointed (filed 2026-05-06).
New leaders reset buying decisions — get the Full Report on Bionano Genomics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Bionano Genomics, Inc., with the record behind each one.
Find candidates like Chief Executive Officer at Bionano Genomics, Inc.Every change, in the filing's words
Reported
On June 2, 2026, Alka Chaubey, Ph.D. resigned as Chief Medical Officer of Bionano Genomics, Inc. (the "Company") effective July 5, 2026.
Departing: R. Erik Holmlin
In connection with his termination, Dr. Holmlin resigned from the Company's Board of Directors (the "Board") and any committees thereof, effective as of the Effective Date.
Appointed: Albert A. Luderer, Chief Executive Officer
As of the Effective Date, the Board appointed Albert A. Luderer, Ph.D., who currently serves as the Company's Chairman of the Board, as the Company's Interim Chief Executive Officer.
- Departure of President and Chief Executive Officer On May 5, 2026 (the "Effective Date"), Bionano Genomics, Inc. (the "Company") R. Erik Holmlin, Ph.D. was terminated as the Company's President and Chief Executive Officer, effective immediately.
- Dr. Holmlin is entitled to receive severance benefits in accordance with the terms of his employment agreement, subject to execution of a release and the other conditions in such agreement.
- It is expected that Dr. Holmlin will enter into a consulting agreement with the Company, pursuant to which he will serve as a consultant to the Company on an as-needed basis to assist with an orderly transition.
- In this role, he will also serve as the Company's interim principal financial officer.
- Dr. Luderer will continue to serve as Chairman of the Board but, in connection with his appointment, will no longer serve as a member of the Compensation Committee, the Audit Committee and the Nominating and Corporate Governance Committee of the Board.
- The Company intends to promptly commence a search to identify a permanent Chief Executive Officer.
- Dr. Luderer, age 77, has served on the Board since October 2011 and as Chairman of the Board since June 2024.
- Since September 2013, Dr. Luderer has served as the Chief Executive Officer and a member of the board of directors of Indi Molecular, Inc., a private synthetic antibody technology company.
Tools for this story
Each opens in a new tab, filled in for Bionano Genomics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.